Genetic toxicity assessment: Employing the best science for human safety evaluation part I: Early screening for potential human mutagens

Toxicological Sciences

Volumn 96, Issue 1, 2007, Pages 16-20

  Jacobson Kram, David ^a   Contrera, Joseph F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bacterial mutation; Clastogenesis; Mutagenesis; Structure activity

Indexed keywords

CARCINOGEN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; RAD54 PROTEIN; TRIAZOLAM;

ACCURACY; ARTICLE; BACTERIAL MUTATION; CARCINOGENICITY; COMPUTER MODEL; COMPUTER PROGRAM; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC TOXICOLOGY; GENOTOXICITY; GOOD LABORATORY PRACTICE; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MUTAGENESIS; MUTAGENICITY; NONHUMAN; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; BIOLOGICAL ASSAY; CELL LINE; CHROMOSOME ABERRATIONS; COMPUTER SIMULATION; DNA, BACTERIAL; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; GENOMICS; GUIDELINES; HUMANS; MODELS, CHEMICAL; MUTAGENICITY TESTS; MUTAGENS; MUTATION; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 33847311846     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfl191     Document Type: Article

References (24)

1. Ashby, J., and Tennant, R.W., (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 257, 229-306.
2. Bailey, A. B., Chanderbhan, R., Collazo-Braier, N., Cheeseman, M. A., and Twaroski, M. L. (2005). The use of structure-activity relationship analysis in the food contact notification program. Regul. Toxicol. Pharmacol. 42, 225-235.
3. Billinton, N., Barker, M. G., Michel, C. E., Knight, A. W., Heyer, W.-D., Goddard, N. J., Fielden, P. R., and Walmsley, R. M. (1998). Development of a green fluorescent protein reporter for a yeast genotoxicity biosensor. Biosens. Bioelectron. 13, 831-838.
4. Contrera, J. F., Matthews, E. J., Kruhlak, N. L., and Benz, R. D. (2005). In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. Regul. Toxicol. Pharmacol. 43, 313-323.
5. Environmental Protection Agency (EPA). (2006). New Chemicals Program ecological structure activity relationships. Available at: http://www.epa.gov/oppt/newchems/tools/21ecosar.htm. Accessed January 1, 2007.
6. Fluckiger-Isler, S., Baumeister, M., Braun, K., Gervais, V., Hasler-Nguyen, N., Reimann, R., Van Gompel, J.,Wunderlich, H. G., and Engelhardt, G. (2004). Assessment of the performance of the Ames II assay: A collaborative study with 19 coded compounds. Mutat. Res. 558, 181-197.
7. Gold, L. S., and Zeiger, E. (1997). Handbook of Carcinogenic Potency and Genotoxicity Databases. CRC Press, Boca Raton, FL.
8. Hastwell, P. W., Chai, L. L., Roberts, K. J., Webster, T. W., Harvey, J. S., Rees, R. W., and Walmsley, R. M. (2006). High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat. Res. 607, 160-175.
9. ICH S2A. (1995). Genetic toxicity studies: Guidance on specific aspects of regulatory tests for pharmaceuticals. Available at: www.ich.org. Accessed January 1, 2007.
10. ICH S2B. (1997). Genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals. Available at: www.ich.org. Accessed January 1, 2007.
11. Kirkland, D., Aardema, M., Henderson, L., and Muller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584, 1-256.
12. Kruhlak, N. L., Contrera, J. F., Benz, R. D., and Matthews, E. J. (2007). Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv. Drug Deliv. Rev. (in press).
13. Matthews, E. J. Kruhlak, N. L., Cimino, M. C., Benz, R. D., and Contrera, J. F. (2006a). An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. Regul. Toxicol. Pharmacol. 44, 83-96.
14. Matthews, E. J., Kruhlak, N. L., Cimino, M. C., Benz, R. D., and Contrera, J. F. (2006b). An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants and reprotoxicants using in silico methods. Regul. Toxicol. Pharmacol. 44, 97-110.
15. Miller, B., Albertini, S., Locher, F., Thybaud, V., and Lorge, E. (1997). Comparative evaluation of the in vitro micronucleus test and the in vitro chromosome aberration test: Industrial experience. Mutat. Res. 392, 45-59.
16. National Institutes of Health, National Library of Medicine. (2005). U.S. Environmental Protection Agency, Office of Prevention, Pesticides and Toxic Substances - GENE-TOX Agent Registry. Online computer database - TOXNET file. U.S. Department of Health and Human Services. Bethesda, MD 20894.
17. McGee, P. (2005). Modeling success with in silico tools. Drug Discov. Dev. 8, 24-28.
18. Pearl, G. M., Livingston-Carr, S., and Durham, S. K. (2001). Integration of computational analysis as a sentinel tool in toxicological assessments. Curr. Top. Med. Chem. 1, 247-255.
19. Pennie, W., Pettit, S. D., and Lord, P. G. (2004). Toxicogenomics in risk assessment: An overview of an HESI collaborative research program. Environ. Hlth. Perspec. 112, 439-448.
20. Piegorsch, W. W., and Zeiger, E. (1991). Measuring intra-assay agreement for the Ames Salmonella assay. In L. Hotorn (ed.) Statistical Methods in Toxicology, Lecture Notes in Medical Informatics, pp. 35-41. vol. 43. Springer-Verlag, Heidelberg, Germany.
21. Tropsha, A., Gramatica, P., and Gombar, V. K. (2003). The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. Quant. Struct. Act. Relat. 22, 1-9.
22. U.S. Food and Drug Administration (FDA). (2004). Challenge and opportunity on the critical path to new medical products, pp. 1-21. Available at: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html. Accessed January 1, 2007.
23. Snyder, R. D. and Green J.W. (2001). A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488, 151-169.
24. Van Gompel, J., Woestenborghs, F., Beerens, D., Mackie, C., Cahill, P. A., Knight, A. W., Billinton, N., Tweats, D. J., and Walmsley, R. M. (2005). An assessment of the utility of the yeast GreeenScreen assay in pharmaceutical screening. Mutagenesis 20, 449-454.